19 Results

Novel CMV Vaccine Generates Stronger Response in Key Immune Cells Than Previous Candidate

A messenger RNA (mRNA) vaccine designed to prevent human cytomegalovirus (CMV) elicited long-lasting CMV-specific responses from several types of immune cells, outperforming a previous vaccine concept in multiple measures in a NIAID-supported laboratory study. The findings were published in the Journal of Infectious Diseases.

The STOMP trial evaluates an antiviral for mpox

NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial.

Promising Experimental Vaccine for Tick-borne Kyasanur Forest Disease Virus

With ticks expanding their territories in many parts of the world, a NIAID research group has likewise expanded its promising vaccine research to two typically rare pathogens with potential for public health importance -- Kyasanur Forest disease and Alkhurma hemorrhagic fever.

NIAID’s VRC, S. Africa’s Afrigen Kick Off Vaccine-Sharing Efforts

A team of vaccine production experts from South Africa recently finished training with NIAID Vaccine Research Center scientists. Their objective: to globally produce vaccines against a list of troubling infectious diseases.

Hepatitis B and C—A Closer Look at NIAID Research to Accelerate Elimination

Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...

IAS 2023—HIV Vaccines, bNAbs, and an Update from NIH’s Office of AIDS Research

This blog is cross-posted from 

On Tuesday at the International AIDS Society’s 12th Conference on HIV Science (IAS 2023), continued our conversations about research highlights, including a focus on the latest about HIV vaccines. We also heard an update from the NIH Office of AIDS Research.

NIH’s Carl Dieffenbach, Ph.D., Director of the Division of AIDS at the National Institute...

Promising Advances for Antibody Treatment of Viruses that Cause Neurologic and Arthritic Diseases

NIAID scientists and colleagues are one step closer to developing a safe and effective therapy against alphaviruses, which are spread by mosquitoes and can cause two types of disease in people: causing severe neurological impairment such as encephalitis (brain swelling) or crippling muscle pain similar to arthritis.

Register Now! Live with Leadership—A Conversation Commemorating National HIV Vaccine Awareness Day

Register now to take part in an important conversation about National HIV Vaccine Awareness Day—an annual observation to recognize the many community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. The Live with Leadership conversation will take place on Thursday, May 18, from 2:30–3:00pm ET.

Register Now!

This engaging...

Universal Influenza Candidate Vaccine Performs Well in Phase 1 Trial

Developing a universal influenza vaccine is a significant priority for NIAID scientists. Two new studies describe a unique candidate developed by NIAID's Vaccine Research Center that performed well in a Phase 1 clinical trial.

NIAID-Supported Studies Identify Universal Predictors of Antibody Response to Vaccination

Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.

2 NIAID Studies Highlight COVID-19 Nasal Vaccine Potential

As scientists learn more about SARS-CoV-2 and its infection tactics, nasal vaccines appear to be a promising response.

NIAID Issues Further Awards to Support Pan-Coronavirus Vaccine Development

Developing a vaccine capable of fighting a diverse group of coronaviruses and viral variants remains a priority for NIAID, which NIAID has awarded an additional $26.1 million for four additional “pan-coronavirus” vaccine grant awards,

NIH Continues Investment in HIV Prevention, Therapy and Cure with $34 Million Award

The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology

NIAID-Funded Adjuvant Improves Typhoid Vaccine Candidate in Animal Studies

An investigational typhoid vaccine containing a component developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine in June.

NIAID Mouse Study Shows Benefits of COVID-19 Nasal Vaccine vs. Intramuscular

A new comparison study in PNAS from NIAID intramural scientists clearly shows that for SARS-CoV-2, nasal vaccination – particularly in two doses – has clear advantages over muscular delivery in laboratory mice.

NIAID Study Searches for Answers in Mystery of Long COVID

NIAID investigators recently published initial results from a study seeking to characterize and better understand persistent symptoms some people experience after having COVID. These persistent symptoms, often referred to as “long COVID,” can sometimes be debilitating, and their cause is currently unknown. This single-site study is part of a larger research effort across multiple institutes at NIH and NIH-funded institutions to understand, prevent, and treat long-term health effects related to COVID-19.

How Children are Helping Scientists Battle a ‘List of Bad Viruses’

The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.

NIAID Observes HIV Vaccine Awareness Day 2022

Today marks the 25th anniversary of the first HIV Vaccine Awareness Day. Although tremendous progress has been made over the past several decades in HIV treatment and prevention, the development of a safe, effective, and durably protective vaccine to prevent HIV infection has, unfortunately, remained elusive. On this commemorative day, NIAID acknowledges the disappointments of the past while optimistically looking ahead to what’s next in HIV vaccine development. 

NIH’s Dr. Carl Dieffenbach Discusses Highlights of HIV Cure, Treatment and Prevention Research from CROI 2022

In an video conversation on February 16, NIAID's Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022). Dr. Dieffenbach, who directs the Division of AIDS, covered developments in HIV cure, treatment and prevention research. Watch the conversation and read summaries of the study findings he discussed.


Contact the NIAID Media Team.